Inositol for PCOS does less than the 40 to 1 label claims

The 2023 International Evidence-based PCOS Guideline rates inositol as a preference-based option with very low certainty.¹ Myo-inositol plus folic acid reduced fasting insulin by a pooled mean difference of −4.17 µU/mL versus folic acid alone in two small trials. The review found no statistically significant differences in BMI, ovulation, or clinical pregnancy for that comparison.² The small trial favoring a 40 to 1 ratio did not establish an optimal formulation for PCOS.⁶¹

01The 2023 PCOS guideline is more cautious than inositol labels

Recommendation 4.7.1 is the marketing claim rewritten as a warning. Inositol of any form could be considered on preference, limited harm, and a possible metabolic nudge. Clinical benefits for ovulation, hirsutism, and weight are listed as limited. The certainty grade is very low. The next two recommendations remove any license to pick a type, a dose, or a fertility claim.¹

Fitz and colleagues wrote the evidence review the guideline actually used. They assessed 43 randomized trials for integrity, dropped 13 for moderate risk, included 30 trials in 2,230 people, and pooled 19.²

Greff's 2023 meta-analysis reached a more favorable conclusion.³ Fitz identified two methodological differences that could help explain the discrepancy: Greff included some studies that Fitz excluded over integrity concerns, and used changes from baseline rather than follow-up values. Fitz could not test both approaches in sensitivity analyses because too few studies were available.²

02Myo-inositol and D-chiro-inositol do different jobs in PCOS

Inositol-derived signaling molecules participate in insulin signaling and glycogen synthesis.¹² D-chiro-inositol has been hypothesized to increase ovarian androgen production and reduce aromatase activity. These proposed mechanisms do not establish the clinical effects of supplementation in people with PCOS.¹³

Nestler's rationale was that muscle and liver can run short of D-chiro-inositol in insulin resistance.⁴ Carlomagno, Unfer, and Roseff hypothesized that the ovary in PCOS already has too much D-chiro-inositol, because insulin-driven epimerase converts myo-inositol locally.¹³ Extra D-chiro-inositol in theca cells is hypothesized to push androgen production and turn aromatase down. Muscle insulin sensitivity and ovarian inositol handling can move in opposite directions on the same person.

High-dose D-chiro-inositol at 1,200 to 2,400 mg is a different exposure than 50 to 100 mg of D-chiro-inositol inside a 4 g myo-inositol mix.

Isabella and Raffone reported poorer oocyte outcomes at higher D-chiro-inositol doses in a small IVF study. The paper now carries expressions of concern. Its results cannot establish a reliable dose-dependent safety rule.⁸

03The 40 to 1 inositol ratio lacks a guideline endorsement

Nordio described 40 to 1 as a physiological plasma ratio, but the trial compared supplement formulations in people with PCOS. It did not measure plasma ratios in healthy women.⁶ A separate study by Unfer and colleagues reported different myo-inositol to D-chiro-inositol ratios in follicular fluid from participants with and without PCOS.⁵

Heimark, McAllister, and Larner also reported differences in theca-cell inositol ratios in PCOS.⁷ Theca cells and follicular fluid are different samples. Neither measurement identifies the best oral supplement ratio.⁵⁷

Nordio compared seven ratios with eight women assigned per arm, 2 g of inositols twice a day for three months, and reported the best results with 40 to 1.⁶ The guideline still finds insufficient evidence to recommend a formulation.¹ In 2025, a separate 2011 oocyte-quality trial by Unfer and colleagues received an expression of concern concerning a possible undeclared conflict involving his role at Loli Pharma.¹⁴

04Myo-inositol trials show limited benefits beyond insulin measures

The following results come from Fitz's meta-analysis. Myo-inositol plus folic acid reduced fasting insulin and HOMA-IR versus folic acid alone, but the review found no statistically significant differences in BMI, ovulation, or clinical pregnancy for that comparison. The certainty of these findings was low or very low. A nonsignificant difference does not prove that treatments are equivalent.²

The ovulation signal that still gets quoted is Nestler 1999. Forty-four women received 1,200 mg of D-chiro-inositol or placebo for six to eight weeks. Nineteen of 22 ovulated in the treatment group versus 6 of 22 on placebo.⁴ Those results belong to that small trial and that formulation. They cannot establish an expected ovulation rate for everyone taking inositol.²

Showell's 2018 Cochrane review of 13 trials in 1,472 subfertile women left live birth too uncertain to act on. The live-birth estimate came from 2 trials and 84 women. Clinical pregnancy was also too uncertain to recommend myo-inositol as IVF pretreatment.¹¹ That is why recommendation 5.8.1 still calls fertility use experimental.¹

The 2025 MYPP trial found no reduction in its pregnancy-complication composite. Van der Wel and colleagues randomized 464 pregnant people with PCOS to 4 g daily myo-inositol plus folic acid or folic acid alone, starting between 8 and 16 weeks of gestation and continuing through delivery. The composite of gestational diabetes, preeclampsia, or preterm birth was 25.0% versus 26.8%, RR 0.93 (95% CI 0.68 to 1.28), P=0.67.⁹

05Metformin performed better for hirsutism and waist-to-hip ratio

Metformin performed better for hirsutism and waist-to-hip ratio in the head-to-head pool; waist circumference did not differ significantly.² The review also cautioned that 23 of 29 trials did not report adverse events. The gastrointestinal difference was no longer statistically significant in the low-risk-of-bias sensitivity analysis.²

The guideline favors metformin over inositol for hirsutism and central adiposity. Medication changes belong in a discussion with the prescribing clinician.¹ Readers comparing supplements can also consult the separate berberine evidence review.

06Studied inositol doses exceed the amounts in tested diets

Several trials used 4 g of myo-inositol daily, often divided into two doses. Other studies used different amounts and combinations.² A ratio alone does not specify the dose. The examples below distinguish a studied regimen, illustrative ratio arithmetic, and the diets measured by Clements and Darnell.²¹⁰

Clements and Darnell measured 487 foods and built 1,800 kcal diets that delivered 225 to 1,500 mg of myo-inositol.¹⁰ Those tested diets were at least 2.5 g below a 4 g supplement regimen. That does not establish an upper limit for every possible diet.

Food intake and a studied supplement dose should therefore be reported separately.¹⁰

07Discuss inositol with your clinician without a fixed response rule

Trial follow-up ranged from completion of an IVF cycle to six months. These studies do not establish a universal 12-week trial period, laboratory response threshold, or stopping rule.²

The guideline advises against routine use of clinically available insulin assays in PCOS. A change in fasting insulin or HOMA-IR in a research study does not validate using that measurement to decide whether an individual should continue a supplement.¹

Treatment depends on the clinical goal. Combined oral contraceptives can be used for hirsutism and/or irregular menstrual cycles. Letrozole is first-line pharmacological ovulation induction for anovulatory infertility in PCOS when there are no other infertility factors.¹

Sustainable eating and physical activity remain part of care, with no single diet composition recommended over all others.¹ The PCOS nutrition guide and macro tracking for insulin resistance provide related practical context.

If you choose inositol, tell your clinician which product you use. Discuss the uncertainty of benefit and variation in supplement quality. The guideline supports shared decision-making, but it does not endorse a specific type, dose, combination, or response-monitoring protocol.¹

08References